iPS Academia Japan, an affiliate of Kyoto University, is engaged in managing and utilizing the patents and other intellectual properties in the field of iPSC technologies so that the research results contribute to health and welfare.
Lonza Bioscience chief operating officer Lukas Utiger said the company is ready to support its clients in navigating the hurdles of process scale-up and optimization, cGMP manufacturing, and regulatory compliance.
"In our pluripotent stem cell technologies group, we continue to help our clients by ‘building bridges from research to therapy," Utiger added.
"With this license in place, we are well positioned to support our clients as they move from the research laboratory to a cGMP cell therapy suite."
Kyoto University center iPS cell research and application director Shinya Yamanaka said, "I hope that the deal will help speed up the movement towards bringing iPS cell-based drug development at the earliest possible stage."
iPS Academia Japan president and chief executive officer Shosaku Murayama said, "Lonza is an ideal partner to drive iPSC technology towards commercial success."